Related Experiment Video

Updated: Aug 30, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Successful treatment of infective endocarditis with recombinant tissue plasminogen activator

Aviva Levitas1, Nili Zucker, Eli Zalzstein

  • 1Department of Pediatric Cardiology, the Pediatric Intensive Care Unit, Faculty of Health Sciences, Ben-Gurion University, Soroka Medical Center, Beer Sheva, Israel. alevitas@bgumail.bgu.ac.il

The Journal of Pediatrics
|November 15, 2003
PubMed

Insights

Recombinant tissue plasminogen activator (r-TPA) effectively treated infectious endocarditis in high-risk infants, resolving vegetations without complications. This therapy offers a safe alternative to surgery for pediatric infectious endocarditis.

Area of Science:

  • Pediatric Cardiology
  • Infectious Diseases
  • Thrombolytic Therapy

Background:

  • Infectious endocarditis (IE) poses significant risks in high-risk children with indwelling catheters.
  • Drug-resistant IE with persistent vegetations requires effective treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant tissue plasminogen activator (r-TPA) as adjunctive therapy for pediatric infectious endocarditis.
  • To assess the impact of r-TPA on survival and cardiac morbidity in high-risk infants.

Main Methods:

  • Prospective 3-year study (1998-2001) involving high-risk children with IE and sepsis.
  • r-TPA administration in patients with persistent, enlarging intracardiac vegetations unresponsive to conventional treatment.
  • Monitoring of treatment complications, survival rates, and cardiac morbidity.

Main Results:

  • Seven infants received r-TPA treatment.
  • All infants showed prompt resolution of intracardiac vegetations within 3-4 days.
  • No adverse complications were observed, and all patients survived with no long-term cardiac morbidity.

Conclusions:

  • Recombinant tissue plasminogen activator (r-TPA) demonstrated a safe and effective adjunctive treatment for pediatric infectious endocarditis.
  • r-TPA may serve as a viable alternative to surgical intervention in high-risk infants with IE.
Abstract

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.